AgResults Issues for RFP for Global Brucellosis Vaccine Prize

AgResults is an $118 million initiative of the governments of Australia, Canada, the United Kingdom, and United States and the Bill & Melinda Gates Foundation to incentivize and reward high-impact agricultural innovations that promote global food security, health, and nutrition and benefit smallholder farmers.

To advance this mission, the initiative has issued a Call for Proposals for a competition that leads to the development of a brucellosis vaccine that improves the livelihoods of smallholder farmers in developing countries.

Brucellosis is a disease that affects ruminants (cattle, sheep, goats, buffalo, etc.) and causes abortions, infertility, decreased milk production, and weight loss, among other effects. It is endemic in a number of developing countries, and the toll on smallholder farmers in South Asia and sub-Saharan Africa is particularly devastating, as cattle and small ruminants such as goats and sheep are a crucial source of income for this population. Brucellosis also is the most common type of disease transmitted from animals to humans, with approximately five hundred thousand new human cases reported each year.

Through the $30 million Brucellosis Vaccine Prize, AgResults invites vaccine developers to submit their proposals for the development of a vaccine that is efficacious, safe, and viable for use against Brucella melitensis in small ruminants across the developing world.

The pilot prize program will be managed by the Global Alliance for Livestock Veterinary Medicines (GALVmed).

The competition is open to organizations with demonstrable experience and expertise in all of the following: research, development, registration, manufacturing, and the commercialization of animal health vaccines.

Applications to become a "solver" and enter the first phase of the competition — through which ten prizes of $100,000 each will be awarded — must be received no later than November 18, 2017.

See the AgResults website for complete program guidelines, a detailed FAQ, and application instructions.